Vaccinations started today of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK. Professor Tom\u00e1\u0161 Hanke, Professor of Vaccine Immunology at the Jenner Institute and lead researcher on the trial, said: \u2018An effective HIV vaccine has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy in both HIV-negative individuals for prevention and in people living with HIV for cure.\u2019
The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine \u2018AZD2816\u2019 in volunteers against the B.1.351 variant of concern \u2013 commonly known as the Beta variant.
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study. Mixed schedules involving Pfizer-BioNTech and Oxford-AstraZeneca generate strong immune response against SARS-CoV2 spike IgG protein.
Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose. Additionally, a third dose of the vaccine continues to boost antibodies against SARS-CoV-2.
The pioneering work of members of the University into tackling the Coronavirus pandemic has been recognised in The Queen's Birthday Honours List. The honorands include Jenner Institute researchers Sarah Gilbert, Catherine Green, Adrian Hill and Teresa Lambe.
Researchers running the University of Oxford-led Com-COV study \u2013 launched earlier this year to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine \u2013 have today reported preliminary data revealing more frequent mild to moderate reactions in mixed schedules compared to standard schedules.
Professor Adrian Hill is elected as Fellow of the Royal Society for his world-leading work in the design and development of new vaccines for globally important infectious diseases. He founded and directs the Jenner Institute at Oxford University.
Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up.
COVID-19 infections fell significantly \u2013 by 65% percent - after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study.
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.\r\n\r\nBoth the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the EU's European Medicines Agency have concluded that whilst there was a possible link from these very rare blood clots to the vaccine, the benefits of vaccination continue to outweigh the risks in all age groups, and have requested the product information is updated to mitigate further risks.
Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
The VALIDATE Network, a community of over 400 researchers based in more than 200 research institutions in 63 countries, will today launch the \u201cBCG100 Programme\u201d marking the centenary of the Bacille Calmette-Gu\u00e9rin Vaccine for tuberculosis. BCG100 officially launches with the \u2018BCG Then and Now\u2019 online lecture by Professor Helen McShane, VALIDATE Network Director and Jenner Investigator and Professor Paul Fine, London School of Hygiene and Tropical Medicine. Taking place at 6pm GMT, 24 March 2021, the talk will cover the initial development of the vaccine, moving through to the modern-day challenges in the fight against TB and the future challenges researchers face in replacing the enduring BCG vaccine.
A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.
Scientists at the University of Oxford have released pre-print data measuring the level of antibodies that can neutralise \u2013 or stop infection from \u2013 variants that are circulating in South Africa, Brazil and elsewhere. These data suggest that natural- and vaccine-induced antibodies can still neutralise these variants, but at lower levels. Importantly, the P1 \u2018Brazilian\u2019 strain may be less resistant to these antibodies than first feared.
Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce\u2019 (RSA) Albert Medal for her work on the Oxford vaccine. The lead researcher on the Oxford vaccine team, Professor Gilbert is Professor of Vaccinology in the Nuffield Department of Medicine at the University of Oxford. She is the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world.
Today Public Health England (PHE) has submitted a pre-print of a real-world study that shows that the Oxford / AstraZeneca and Pfizer vaccines are both highly effective in reducing COVID-19 infections among older people aged 70 years and over. Both vaccines had about 60% protection against symptomatic infection in this age group.
The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
WHO SAGE says Oxford's vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group. The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) yesterday produced guidelines for the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford with its partner AstraZeneca.
![\"Generic](\"https://www.jenner.ac.uk/about/news/hiv-vaccine-trial-starts-at-oxford/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n